WAYNE, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today…
- FDA meeting facilitated positive collaborative exchange -- Key topics included the clinical study protocol synopsis, the benefits versus risks…
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel,…
CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), (formerly Blue Water Biotech, Inc.…
LAKELAND, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- In the realm of men's health, particularly as they age, prostate health…
Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide…
On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL…
First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian…
Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate…
– Latest BOND-003 data show 75.5% of patients achieved a complete response at any time –– Median duration of response…